Safety and immunogenicity of an investigational adjuvanted hepatitis B vaccine (HB-AS02V) in healthy adults

Human Vaccines

Volumn 6, Issue 7, 2010, Pages 578-584

  Beran, Jirí ^a,b   Hobzova, Lenka ^a   Wertzova, Veronika ^a   Kuriyakose, Sherine ^c   Leyssen, Maarten ^d   Surquin, Murielle ^e   Houard, Sophie ^f  

^a Vaccination and Travel Medicine Centre   (Czech Republic)

^b UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^c GlaxoSmithKline Pharmaceuticals Ltd   (India)

^d GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^e BRUGMANN UNIVERSITY HOSPITAL   (Belgium)

^f Henogen SA   (Belgium)

Author keywords

Adjuvant system; HB AS02; Hepatitis B virus infection; Immunogenicity; Renal insufficiency; Seroprotection; Vaccination

Indexed keywords

HB AS02 VACCINE; HEPATITIS B ANTIBODY; HEPATITIS B VACCINE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTHRALGIA; ARTICLE; CHILL; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; GEOMETRY; HEPATITIS B; HUMAN; IMMUNOGENICITY; INJECTION SITE PAIN; INJECTION SITE REDNESS; INJECTION SITE SWELLING; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SEROLOGY; SYMPTOM; TREATMENT DURATION; VACCINATION; VACCINE PRODUCTION; VOMITING;

EID: 77957014168     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.6.7.11883     Document Type: Article

References (30)

1. Zanetti AR, Van Damme P, Shouval D. The global impact of vaccination against hepatitis B: A historical overview. Vaccine 2008; 26:6266-73.
2. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11:97-107. (Pubitemid 38365759)
3. World Health Organization (WHO). Hepatitis B. Fact sheet No204. Revised August 2008. Available at: http://www.who.int/mediacentre/factsheets/fs204/en/. Accessed 2010.
4. Wong PN, Fung TT, Mak SK, Lo KY, Tong GM, Wong Y, et al. Hepatitis B virus infection in dialysis patients. J Gastroenterol Hepatol 2005; 20:1641-51.
5. Peces R, Laurés AS. Persistence of immunologic memory in long-term hemodialysis patients and healthcare workers given hepatitis B vaccine: role of a booster dose on antibody response. Nephron 2001; 89:172-6. (Pubitemid 32830606)
6. Bel'eed K, Wright M, Eadington D, Farr M, Sellars L. Vaccination against hepatitis B infection in patients with end stage renal disease. Postgrad Med J 2002; 78:538-40.
7. DaRoza G, Loewen A, Djurdjev O, Love J, Kempston C, Burnett S, et al. Stage of chronic kidney disease predicts seroconversion after hepatitis B immunization: earlier is better. Am J Kid Dis 2003; 42:1184-92. (Pubitemid 37486762)
8. Garçon N, Chomez P, Van Mechelen M. GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines 2007; 6:723-39. (Pubitemid 47607848)
9. European Medicines Agency (EMEA). European Public Assessment Reports (EPARs) for authorized medicinal products for human use. Fendrix. EPAR H-C-50. Available at: http://www.emea.europa.eu/humandocs/ Humans/EPAR/fendrix/fendrix.htm. Accessed 2010.
10. V- adjuvanted hepatitis B vaccine. Kidney Int 2010; 77:247-55.
11. Vandepapelière P, Horsmans Y, Moris P, Van Mechelen M, Janssens M, Koutsoukos M, et al. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers. Vaccine 2008; 26:1375-86.
12. Sezer S, Ozdemir FN, Güz G, Arat Z, Colak T, Sengul S, et al. Factors influencing response to hepatitis B virus vaccination in hemodialysis patients. Transplant Proc 2000; 32:607-8. (Pubitemid 30254424)
13. Ramezani A, Velayati AA, Eslamifar A, Banifazl M, Ahmadi F, Maziar S, et al. Persistence of hepatitis B vaccine immunity in hemodialysis patients. Ther Apher Dial 2008; 12:143-6.
14. Ramezani A, Eslamifar A, Banifazl M, Ahmadi F, Maziar S, Razeghi E, et al. Efficacy and long-term immunogencitiy of hepatitis B vaccine in haemodialysis patients. Int J Clin Pract 2009; 63:394-7.
15. Salisbury DM, Begg NT. Immunisation against Infectious Diseases. HM Stationary Office: London 1996; 95-108.
16. Impfempfehlungen der ständigen impfkommission (STIKO) an RKI. Epidemiogisches Bulletin No. 2, Robert Koch Institut, Berlin 2000.
17. Keating GM, Noble S. Recombinant hepatitis B vaccine (Engerix-B): a review of its immunogenicity and protective efficacy against hepatitis B. Drugs 2003; 63:1021-51.
18. Barry M, Cooper C. Review of hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine safety and efficacy. Expert Opin Biol Ther 2007; 7:1731-7.
19. Halperin SA, Dobson S, McNeil S, Langley JM, Smith B, McCall-Sani R, et al. Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults. Vaccine 2006; 24:20-6.
20. Jilg W, Schmidt M, Deinhardt F, Zachoval R. Hepatitis B vaccination: how long does protection last ? Lancet 1984; 458.
21. Jilg W, Schmidt M, Deinhardt F. Persistence of specific antibodies after hepatitis B vaccination. J Hepatol 1988; 6:201-7.
22. European Consensus Group on Hepatitis B Immunity. Are booster immunisations needed for lifelong hepatitis B immunity? Lancet 2000; 355:561-5.
23. Pashine A, Valiante NM, Ulmer JB. Targeting the innate immune response with improved vaccine adjuvants. Nat Med 2005; 11:63-8.
24. Kong NCT, Beran J, Kee SA, Miguel JL, Sánchez C, Bayas JM, et al. Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients. Kidney Int 2005; 68:2298-303.
25. Kong NCT, Beran J, Kee SA, Miguel JL, Sánchez C, Bayas JM, et al. A new adjuvant improves the immune response to hepatitis B vaccine in hemodialysis patients. Kidney Int 2008; 73:856-62.
26. Kundi M. New hepatitis B vaccine formulated with an improved adjuvant system. Expert Rev Vaccines 2007; 6:133-40. (Pubitemid 46607449)
27. Beran J. Safety and immunogenicity of a new hepatitis B vaccine for the protection of patients with renal insufficiency including pre-hemodialysis and hemodialysis patients. Expert Opin Biol Ther 2008; 8:235-47. (Pubitemid 351233716)
28. Bojang KA. RTS, S/AS02A for malaria. Expert Rev Vaccines 2006; 5:611-5.
29. Progress in the control of viral hepatitis: memorandum from a WHO meeting. Bull World Health Organ 1988; 66:443-55.
30. Hepatitis B virus: A comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Recommendations of the Immunization Practices Advisory Committee. MMWR 1991; 40:1-25.